TRANSMEDICS GROUP INC

TMDXNASDAQ

🏆 #1535 by market capEarnings Nov 4US Equity

$86.30▼ $2.95 (−3.42%)

Live

1h▼ 0.7%

24h▼ 3.4%

7d▲ 12.8%

14d▲ 10.6%

30d▲ 14.0%

1y▼ 34.3%

🏦Market Cap

$2.98B

Small Cap

📈Revenue Growth (YoY)

+25.8%

High Growth

📊Gross Margin

58.7%

Healthy

💵FCF Margin

13.6%

Healthy

⚖️P/S Ratio

4.5x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $85.42 – $87.40
52-Week Range: $60.11 – $156.00
Volume: $1.93B
Avg Volume: $2.27B
Shares Outstanding: 34.6M
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $605M
Last Q Revenue: $190M
P/E Ratio: 20.0
P/S Ratio: 4.5x
EPS (TTM): $3.73
Dividend Yield: —

Why Investors Own TMDX

✓High-growth profile — revenue up +4.4% YoY with expanding US Equity exposure.
✓Healthy economics — 75% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$605M▲ +6.8% YoY

Gross Margin (TTM)

75.2%▲ +1.5% YoY

Operating Income (TTM)

$84M▲ +6.8% YoY

Free Cash Flow (TTM)

$139M▲ +6.8% YoY

About TRANSMEDICS GROUP INC

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

🦦